Uncovering the Potent Antiviral Activity of the Sesterterpenoids from the Sponge Ircinia Felix Against Human Adenoviruses: from the Natural Source to the Total Synthesis
Year: 2024
Type: article
Abstract: Human Adenovirus (HAdV) infections in immunocompromised patients can result in disseminated diseases with high morbidity and mortality rates due to the absence of available treatments for these infections. The sponge Ircinia felix was selected for the significant anti‐HAdV activity displayed by its organic extracts. Its chemical analysis yielded three novel sesterterpene lactams, ircinialactams J−L, along with three known sesterterpene furans which structures were established by a deep spectrometric analysis. Ircinialactam J displayed significant antiviral activity against HAdV without significant cytotoxicity, showing an effectiveness 11 times greater than that of the standard treatment, cidofovir®. Comparison of the antiviral evaluation results of the isolated compounds allowed us to deduce some structure‐activity relationships. Mechanistic assays suggest that ircinialactam J targets an early step of the HAdV replicative cycle before HAdV genome reaches the nucleus of the host cell. The first total synthesis of ircinialactam J was also accomplished to prove the structure and to provide access to analogues. Key steps are a regio‐ and stereoselective construction of the trisubstituted Z ‐olefin at Δ 7 by iron‐catalyzed carbometallation of a homopropargylic alcohol, a stereoselective methylation to generate the stereogenic center at C18, and the formation of the ( Z)‐ Δ 20 by stereoselective aldol condensation to introduce the tetronic acid unit. Ircinialactam J is a promising chemical lead to new potent antiviral drugs against HAdV infections.
Source: Chemistry - A European Journal
Authors: Ana Ruiz‐Molina, Dawrin Pech‐Puch, Ramón E. Millán, Lucía Ageitos, Harold Villegas‐Hernández, Jerónimo Pachón, José Pérez Sestelo, Javier Sánchez‐Céspedes, Jaime Rodríguez, Carlos Jiménez
Institutions: Universidade da Coruña, Consejo Superior de Investigaciones Científicas, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Autonomous University of Yucatán, Universidad Nacional Autónoma de México, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red Enfermedades Infecciosas
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,640
Awards: G121809054, Nuevos derivados salicilamida de niclosamida para su uso como agentes antivirales de amplio espectro, G1855990336, G2262748287, G2417350515, G2660406951, G2882975602, G3480869486, G3518946140, G3555816185, G3681454997, G4042783231, G4193446334, G425668148, G4333900429, G4405273986, G5421974903, G5952760049, G659153159, G6791797850, G7084143925, G7224627388, G7946121360
OpenAlex ID: W4402667231
